Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 29.63% is 193% above its 5-year average of -32.00%, near the high end of its 5-year range (-330.34%–100.00%).
49.13% below its 12-month average of 58.25%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
29.63%
GROSS MARGIN AVG TTM
58.25%
GROSS MARGIN AVG 3Y
1.03%
GROSS MARGIN AVG 5Y
-32.00%
GROSS MARGIN AVG 10Y
-99.03%
GROSS MARGIN AVG 15Y
-138.49%
GROSS MARGIN AVG 20Y
-122.31%
CURRENT VS TTM AVG
-49.13%
CURRENT VS 3Y AVG
+2772.87%
CURRENT VS 5Y AVG
+192.58%
CURRENT VS 10Y AVG
+129.92%
CURRENT VS 15Y AVG
+121.40%
CURRENT VS 20Y AVG
+124.22%
SECTOR MEDIAN · HEALTHCARE
47.19%
median of 504 covered companies
CURRENT VS SECTOR MEDIAN
-37.20%
vs the sector median at left
Market Cap
$368.66M
Gross Margin
99.87%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
83.33%
Market Cap
$368.13M
Gross Margin
98.15%
TTM Avg
96.49%
3Y Avg
98.25%
5Y Avg
98.83%
Market Cap
$369.60M
Gross Margin
93.73%
TTM Avg
92.44%
3Y Avg
93.34%
5Y Avg
78.89%
Market Cap
$379.26M
Gross Margin
25.47%
TTM Avg
27.02%
3Y Avg
15.55%
5Y Avg
5.84%
Market Cap
$348.59M
Gross Margin
0.00%
TTM Avg
50.00%
3Y Avg
75.00%
5Y Avg
66.67%
Market Cap
$347.88M
Gross Margin
62.61%
TTM Avg
61.15%
3Y Avg
61.24%
5Y Avg
64.05%
Market Cap
$387.87M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
40.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Agenus Inc. (AGEN) | $353.54M | 29.63% | 58.25% | 1.03% | -32.00% |
| Opus Genetics, Inc. (IRD)vs › | $368.66M | 99.87% | 100.00% | 100.00% | 83.33% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $368.13M | 98.15% | 96.49% | 98.25% | 98.83% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $369.60M | 93.73% | 92.44% | 93.34% | 78.89% |
| Canopy Growth Corporation (CGC)vs › | $379.26M | 25.47% | 27.02% | 15.55% | 5.84% |
| Embecta Corp. (EMBC)vs › | $348.55M | 59.89% | 63.90% | 65.83% | 67.05% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $348.59M | 0.00% | 50.00% | 75.00% | 66.67% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $347.88M | 62.61% | 61.15% | 61.24% | 64.05% |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $387.87M | 0.00% | 0.00% | 25.00% | 40.00% |
| Cabaletta Bio, Inc. (CABA)vs › | $342.42M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
29.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 98.27% |
| 2025-12-31 | 78.04% |
| 2025-09-30 | 19.83% |
| 2025-06-30 | -4.91% |
| 2025-03-31 | 10.00% |
| 2024-12-31 | -26.29% |
| 2024-09-30 | -64.08% |
| 2024-06-30 | -56.90% |
| 2024-03-31 | 87.57% |
| 2023-12-31 | 20.07% |
| 2023-09-30 | -112.82% |
| 2023-06-30 | -135.37% |
| 2023-03-31 | -159.42% |
| 2022-12-31 | -114.80% |
| 2022-09-30 | -103.40% |
| 2022-06-30 | -124.52% |
| 2022-03-31 | -65.70% |
| 2021-12-31 | -168.33% |
| 2021-09-30 | 82.70% |
| 2021-06-30 | -330.34% |
| 2021-03-31 | -222.40% |
| 2020-12-31 | -16.34% |
| 2020-09-30 | -122.80% |
| 2020-06-30 | -45.42% |
| 2020-03-31 | -140.37% |
| 2019-12-31 | -6.76% |
| 2019-09-30 | -131.35% |
| 2019-06-30 | -187.90% |
| 2019-03-31 | 49.77% |
| 2018-12-31 | -458.58% |
| 2018-09-30 | -133.19% |
| 2018-06-30 | -84.17% |
| 2018-03-31 | -1699.54% |
| 2017-12-31 | -281.52% |
| 2017-09-30 | -667.66% |
| 2017-06-30 | -513.83% |
| 2017-03-31 | -21.09% |
| 2016-12-31 | -365.98% |
| 2016-09-30 | -385.56% |
| 2016-06-30 | -239.23% |
| 2016-03-31 | -320.17% |
| 2015-12-31 | -134.97% |
| 2015-09-30 | -170.18% |
| 2015-06-30 | -288.47% |
| 2015-03-31 | -133.24% |
| 2014-12-31 | -355.16% |
| 2014-09-30 | -238.02% |
| 2014-06-30 | -69.91% |
| 2014-03-31 | -520.39% |
| 2013-12-31 | -726.46% |
| 2013-09-30 | -439.81% |
| 2013-06-30 | -332.96% |
| 2013-03-31 | -154.91% |
| 2012-12-31 | -145.32% |
| 2012-09-30 | 75.03% |
| 2012-06-30 | 79.59% |
| 2012-03-31 | 99.82% |
| 2011-12-31 | 100.00% |
| 2011-09-30 | -679268.22% |
| 2011-06-30 | -598057.25% |
| 2011-03-31 | -747418.38% |
| 2010-12-31 | 87.63% |
| 2010-09-30 | 89.58% |
| 2010-06-30 | 92.81% |
| 2010-03-31 | -775288.28% |
| 2009-12-31 | 100.00% |
| 2009-09-30 | -710119.17% |
| 2009-06-30 | -624184.79% |
| 2009-03-31 | -1317605.69% |
| 2008-12-31 | 100.00% |
| 2008-09-30 | -1437809.86% |
| 2008-06-30 | -1846274.64% |
| 2008-03-31 | -1194107.64% |
| 2007-12-31 | 100.00% |
| 2007-09-30 | -1141745.01% |
| 2007-06-30 | -623596.06% |
| 2007-03-31 | -337549.24% |
| 2006-12-31 | 100.00% |
| 2006-09-30 | -4978081.39% |
| 2006-06-30 | -14436019.06% |
| 2006-03-31 | -25012715.06% |
| 2005-12-31 | 100.00% |
| 2005-09-30 | -22314.74% |
| 2005-06-30 | -24796.86% |
| 2005-03-31 | -14841.09% |
| 2004-12-31 | 100.00% |
| 2004-09-30 | 98.30% |
| 2004-06-30 | -9147.20% |
| 2004-03-31 | -32.84% |
| 2003-12-31 | 58.04% |
| 2003-09-30 | 42.14% |
| 2003-06-30 | 50.31% |
| 2003-03-31 | 65.14% |
| 2002-12-31 | 57.14% |
| 2002-09-30 | 65.87% |
